Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office (USPTO) has granted a US Patent No. 7,994,197 to MAP Pharmaceuticals' Levadex, a proprietary formulation of dihydroergotamine (DHE).
Subscribe to our email newsletter
Levadex is an orally inhaled investigational drug which is used for acute treatment of migraine in adults that targets the pharmacokinetic profiles as described in the patent.
MAP Pharmaceuticals president and CEO Timothy Nelson said they have designed Levadex to overcome the limitations of currently available migraine therapies by combining their formulation capabilities with their proprietary Tempo inhaler, and to target an optimal pharmacokinetic profile for rapid relief of migraine while minimizing side effects.
MAP Pharmaceuticals has partnered with Allergan to co-promote Levadex to neurologists and pain specialists in the US and Canada.